Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
作者： Yichao Wan , Ningning Dai , Zilong Tang , Hao Fang
DOI: 10.1016/J.EJMECH.2018.01.076
关键词:
摘要: The anti-apoptotic members of B-cell lymphoma-2 (Bcl-2) proteins family, such as Bcl-2 and myeloid cell leukemia-1 (Mcl-1), are the key regulators intrinsic pathway apoptosis overexpressed in many tumor cells, which have been confirmed potential drug targets for cancers. A number inhibitors developed conducted clinical trials, but no Mcl-1 presented clinics. In addition, is an important reason resistance to radio- chemotherapies, including that target other family members. For example, recently launched Bcl-2-selective inhibitor ABT-199 displays highly potency treatment chronic lymphocytic leukemia (CLL), it cannot induce controlled by some lines. Therefore, developing potent become urgently needed therapy. This review briefly introduces structure protein, role cancers focuses on progress small-molecule from 2012 2017.
sci-hub.se 参考文章(72)
Shinichi Kitada, Maryla Krajewska, Jurgita Sauvageot, Ahmed Shabaik, Stanislaw Krajewski, Jonathan I. Epstein, John C. Reed, Ki Song, Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. American Journal of Pathology. ,vol. 148, pp. 1567- 1576 ,(1996)
Anthony W. Tolcher, Patricia LoRusso, Jennifer Arzt, Todd A. Busman, Guinan Lian, Niki S. Rudersdorf, Carol Ann Vanderwal, Whitney Kirschbrown, Kyle D. Holen, Lee S. Rosen, Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology. ,vol. 76, pp. 1025- 1032 ,(2015) , 10.1007/S00280-015-2883-8
A R D Delbridge, A Strasser, The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death & Differentiation. ,vol. 22, pp. 1071- 1080 ,(2015) , 10.1038/CDD.2015.50
Dirk Brenner, Heiko Blaser, Tak W. Mak, Regulation of tumour necrosis factor signalling: live or let die Nature Reviews Immunology. ,vol. 15, pp. 362- 374 ,(2015) , 10.1038/NRI3834
M J Roy, A Vom, P E Czabotar, G Lessene, Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway British Journal of Pharmacology. ,vol. 171, pp. 1973- 1987 ,(2014) , 10.1111/BPH.12431
Mark N. Stein, Maha Hussain, Walter M. Stadler, Glenn Liu, Irina V. Tereshchenko, Susan Goodin, Chandrika Jeyamohan, Howard L. Kaufman, Janice Mehnert, Robert S. DiPaola, A Phase II Study of AT-101 to Overcome Bcl-2–Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer Clinical Genitourinary Cancer. ,vol. 14, pp. 22- 27 ,(2016) , 10.1016/J.CLGC.2015.09.010
Jennifer R. Brown, Bethany Tesar, Lijian Yu, Lillian Werner, Naoko Takebe, Evgeny Mikler, Hazel M. Reynolds, Christina Thompson, David C. Fisher, Donna Neuberg, A. S. Freedman, Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia Leukemia & Lymphoma. ,vol. 56, pp. 3336- 3342 ,(2015) , 10.3109/10428194.2015.1048441
Angela M. Keuling, Kathleen E. A. Felton, Arabesque A. M. Parker, Majid Akbari, Susan E. Andrew, Victor A. Tron, RNA Silencing of Mcl-1 Enhances ABT-737-Mediated Apoptosis in Melanoma: Role for a Caspase-8-Dependent Pathway PLoS ONE. ,vol. 4, pp. e6651- ,(2009) , 10.1371/JOURNAL.PONE.0006651
K. M. Kozopas, T. Yang, H. L. Buchan, P. Zhou, R. W. Craig, MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 90, pp. 3516- 3520 ,(1993) , 10.1073/PNAS.90.8.3516
Xiao Ding, Yan Li, Li Lv, Mi Zhou, Li Han, Zhengxi Zhang, Qian Ba, Jingquan Li, Hui Wang, Hong Liu, Renxiao Wang, De novo design, synthesis and evaluation of benzylpiperazine derivatives as highly selective binders of Mcl-1. ChemMedChem. ,vol. 8, pp. 1986- 2014 ,(2013) , 10.1002/CMDC.201300316